Enhanced expression of LINE-1-encoded ORF2 protein in early stages of colon and prostate transformation

Oncotarget

Volumn 7, Issue 4, 2016, Pages 4048-4061

  De Luca, Chiara ^a   Guadagni, Fiorella ^b   Sinibaldi Vallebona, Paola ^c,f   Sentinelli, Steno ^d   Gallucci, Michele ^d   Hoffmann, Andreas ^e   Schumann, Gerald G ^e   Spadafora, Corrado ^f   Sciamanna, Ilaria ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^e PAUL EHRLICH INSTITUT   (Germany)

^f INSTITUTE OF TRANSLATIONAL PHARMACOLOGY   (Italy)

Author keywords

LINE 1 L1; ORF2; Retrotransposon; Reverse transcriptase; Tumorigenesis

Indexed keywords

CELL PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CHA1 L1; ORF1 PROTEIN; ORF2 PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG; DEOXYRIBONUCLEASE I; ENDONUCLEASE; LINE-1 ENDONUCLEASE, HUMAN; ORF2 PROTEIN, HUMAN; RNA DIRECTED DNA POLYMERASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BREAST TUMOR; CANCER STAGING; COLON CANCER; COLON TUMOR; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; LONG INTERSPERSED ELEMENT 1; LUNG TUMOR; MOUSE; NONHUMAN; PROSTATE CANCER; PROSTATE TUMOR; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RETROPOSON; TUMOR GROWTH; ADENOCARCINOMA; ADENOMA; ANIMAL; ANTIBODY PRODUCTION; BAGG ALBINO MOUSE; CANCER GRADING; CELL TRANSFORMATION; ENZYME IMMUNOASSAY; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOLOGY; MALE; METABOLISM; PATHOLOGY; PROGNOSIS; TISSUE MICROARRAY; TUMOR CELL CULTURE; WESTERN BLOTTING;

ADENOCARCINOMA; ADENOMA; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; BIOMARKERS, TUMOR; BLOTTING, WESTERN; CELL TRANSFORMATION, NEOPLASTIC; COLONIC NEOPLASMS; DEOXYRIBONUCLEASE I; ENDONUCLEASES; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MICE; MICE, INBRED BALB C; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; RNA-DIRECTED DNA POLYMERASE; TISSUE ARRAY ANALYSIS; TUMOR CELLS, CULTURED;

EID: 84957990142     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6767     Document Type: Article

References (57)

1. International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature. 2001; 409:860-921.
2. Mathias SL, Scott AF, Kazazian HH Jr., Boeke JD, Gabriel A. Reverse transcriptase encoded by a human transposable element. Science. 1991; 254:1808-10.
3. Brouha B, Schustak J, Badge RM, Lutz-Prigge S, Farley AH, Moran JV, Kazazian HH Jr. Hot L1s account for the bulk of retrotransposition in the human population. Proc. Natl Acad Sci. USA 2003; 100:5280-5.
4. Szak ST, Pickeral OK, Makalowski W, Boguski MS, Landsman D, Boeke JD. Molecular archeology of L1 insertions in the human genome. Genome Biol. 2002; 3:research0052.
5. Schulz WA. L1 retrotransposons in human cancers. J Biomed Biotechnol. 2006; 2006:83672.
6. Belancio VP, Roy-Engel AM, Pochampally RR, Deininger P. Somatic expression of LINE-1 elements in human tissues. Nucleic Acids Res. 2010; 38:3909-22.
7. Wallace NA, Belancio VP, Deininger PL. L1 mobile element expression causes multiple types of toxicity. Gene. 2008; 419:75-81.
8. Goodier JL, Kazazian HH Jr. Retrotransposons revisited:the restraint and rehabilitation of parasites. Cell. 2008; 135:23-35.
9. Hata K, Sakaki Y. Identification of critical CpG sites for repression of L1 transcription by DNA methylation. Gene. 1997; 189:227-34.
10. Jones PA, Liang G. Rethinking how DNA methylation patterns are maintained. Nat Rev Genet. 2009; 10:805-11.
11. Miousse IR, Koturbash I. The Fine LINE:Methylation Drawing the Cancer Landscape. Biomed Res Int. 2015; 2015:131547.
12. Rodic N, Burns KH. Long interspersed element-1 (LINE-1): passenger or driver in human neoplasms? PLoS Genet. 2013; 9:e1003402.
13. Carreira PE, Richardson SR, Faulkner GJ. L1 retrotransposons, cancer stem cells and oncogenesis. FEBS J. 2014; 281:63-73.
14. Sciamanna I, Landriscina M, Pittoggi C, Quirino M, Mearelli C, Beraldi R, Mattei E, Serafino A, Cassano A, Sinibaldi-Vallebona P, Garaci E, Barone C, Spadafora C. Inhibition of endogenous reverse transcriptase antagonizes human tumor growth. Oncogene. 2005; 24:3923-31.
15. Sciamanna I, Gualtieri A, Cossetti C, Osimo EF, Ferracin M, Macchia G, Aricò E, Prosseda G, Vitullo P, Misteli T, Spadafora C. A tumor-promoting mechanism mediated by retrotransposon-encoded reverse transcriptase is active in human transformed cell lines. Oncotarget. 2013; 4:2271-87. doi:10.18632/oncotarget.1403.
16. Oricchio E, Sciamanna I, Beraldi R, Tolstonog GV, Schumann GG, Spadafora C. Distinct roles for LINE-1 and HERV-K retroelements in cell proliferation, differentiation and tumor progression. Oncogene. 2007; 26:4226-33.
17. Rossi A, Russo G, Puca A, La Montagna R, Caputo M, Mattioli E, Lopez M, Giordano A, Pentimalli F. The antiretroviral nucleoside analogue Abacavir reduces cell growth and promotes differentiation of human medulloblastoma cells. Int J Cancer. 2009; 125:235-43.
18. Carlini F, Ridolfi B, Molinari A, Parisi C, Bozzuto G, Toccacieli L, Formisano G, De Orsi D, Paradisi S, Grober OM, Ravo M, Weisz A, Arcieri R, et al. The reverse transcription inhibitor abacavir shows anticancer activity in prostate cancer cell lines. PLoS One. 2010; 5:e14221.
19. Aschacher T, Sampl S, Käser L, Bernhard D, Spittler A, Holzmann K, Bergmann M. The combined use of known antiviral reverse transcriptase inhibitors AZT and DDI induce anticancer effects at low concentrations. Neoplasia. 2012; 14:44-53.
20. Stefanidis K, Loutradis D, Vassiliou LV, Anastasiadou V, Kiapekou E, Nikas V, Patris G, Vlachos G, Rodolakis A, Antsaklis A. Nevirapine induces growth arrest and premature senescence in human cervical carcinoma cells. Gynecol Oncol. 2008; 111:344-9.
21. Dong JJ, Zhou Y, Liu YT, Zhang ZW, Zhou XJ, Wang HJ, Liao L. In vitro evaluation of the therapeutic potential of nevirapine in treatment of human thyroid anaplastic carcinoma. Mol Cell Endocrinol. 2013; 370:113-8.
22. Patnala R, Lee SH, Dahlstrom JE, Ohms S, Chen L, Dheen ST, Rangasamy D. Inhibition of LINE-1 retrotransposon-encoded reverse transcriptase modulates the expression of cell differentiation genes in breast cancer cells. Breast Cancer Res Treat. 2014; 143:239-53.
23. Hecht M, Erber S, Harrer T, Klinker H, Roth T, Parsch H, Fiebig N, Fietkau R, Distel LV. Efavirenz Has the Highest Anti-Proliferative Effect of Non-Nucleoside Reverse Transcriptase Inhibitors against Pancreatic Cancer Cells. PLoS One. 2015; 10:e0130277.
24. Houédé N, Pulido M, Mourey L, Joly F, Ferrero JM, Bellera C, Priou F, Lalet C, Laroche-Clary A, Raffin MC, Ichas F, Puech A, Piazza PV. A phase II trial evaluating the efficacy and safety of efavirenz in metastatic castration-resistant prostate cancer. Oncologist. 2014; 19:1227-8.
25. Sciamanna I, Gualtieri A, Piazza PV, Spadafora C. Regulatory roles of LINE-1-encoded reverse transcriptase in cancer onset and progression. Oncotarget. 2014; 5: 8039-51. doi:10.18632/oncotarget.2504.
26. Gualtieri A, Andreola F, Sciamanna I, Sinibaldi-Vallebona P, Serafino A, Spadafora C. Increased expression and copy number amplification of LINE-1 and SINE B1 retrotransposable elements in murine mammary carcinoma progression. Oncotarget. 2013; 4:1882-93. doi:10.18632/oncotarget.1188.
27. Rodic N, Sharma R, Sharma R, Zampella J, Dai L, Taylor MS, Hruban RH, Iacobuzio-Donahue CA, Maitra A, Torbenson MS, Goggins M, Shih IeM, Duffield AS, et al. Long Interspersed Element-1 protein expression is a hallmark of many human cancers. Am J Pathol. 2014; 184:1280-6.
28. Harris CR, Normart R, Yang Q, Stevenson E, Haffty BG, Ganesan S, Cordon-Cardo C, Levine AJ, Tang LH. Association of nuclear localization of a long interspersed nuclear element-1 protein in breast tumors with poor prognostic outcomes. Genes Cancer. 2010; 1:115-24. doi: 10.1177/1947601909360812.
29. Chen L, Dahlstrom JE, Chandra A, Board P, Rangasamy D. Prognostic value of LINE-1 retrotransposon expression and its subcellular localization in breast cancer. Breast Cancer Res Treat. 2012; 136:129-42.
30. Wang G, Gao J, Huang H, Tian Y, Xue L, Wang W, You W, Lian H, Duan X, Wu B, Wang M. Expression of a LINE-1 endonuclease variant in gastric cancer:its association with clinicopathological parameters. BMC Cancer. 2013; 13:265.
31. Doucet-O'Hare TT, Rodic N, Sharma R, Darbari I, Abril G, Choi JA, Young Ahn J, Cheng Y, Anders RA, Burns KH, Meltzer SJ, Kazazian HH Jr. LINE-1 expression and retrotransposition in Barrett's esophagus and esophageal carcinoma. Proc Natl Acad Sci U S A. 2015; 112:E4894-900.
32. Su Y, Davies S, Davis M, Lu H, Giller R, Krailo M, Cai Q, Robison L, Shu XO. Children's Oncology Group. Expression of LINE-1 p40 protein in pediatric malignant germ cell tumors and its association with clinicopathological parameters: a report from the Children's Oncology Group. Cancer Lett. 2007; 247:204-12.
33. Kimberland ML, Divoky V, Prchal J, Schwahn U, Berger W, Kazazian HH Jr. Full-length human L1 insertions retain the capacity for high frequency retrotransposition in cultured cells. Hum Mol Genet. 1999; 8:1557-60.
34. Cost GJ, Boeke JD. Targeting of human retrotransposon integration is directed by the specificity of the L1 endonuclease for regions of unusual DNA structure. Biochemistry. 1998; 37:18081-93.
35. Sciamanna I, Piccoli S, Barberi L, Zaccagnini G, Magnano AR, Giordano R, Campedelli P, Hodgson C, Lorenzini R, Spadafora C. DNA dose and sequence dependence in sperm-mediated gene transfer. Mol Reprod Dev. 2000; 56:301-5.
36. Belgnaoui SM, Gosden RG, Semmes OJ, Haoudi A. Human LINE-1 retrotransposon induces DNA damage and apoptosis in cancer cells. Cancer Cell Int. 2006; 6:13.
37. Kulpa DA, Moran JV. Cis-preferential LINE-1 reverse transcriptase activity in ribonucleoprotein particles. Nat Struct Mol Biol. 2006; 13:655-60.
38. Raiz J, Damert A, Chira S, Held U, Klawitter S, Hamdorf M, Löwer J, Strätling WH, Löwer R, Schumann GG. The nonautonomous retrotransposon SVA is trans-mobilized by the human LINE-1 protein machinery. Nucleic Acids Res. 2012; 40:1666-83.
39. Luan DD, Korman MH, Jakubczak JL, Eickbush TH. Reverse transcription of R2Bm RNA is primed by a nick at the chromosomal target site:a mechanism for non-LTR retrotransposition. Cell. 1993; 72:595-605.
40. Levin HL, Moran JV. Dynamic interactions between transposable elements and their hosts. Nat Rev Genet. 2011; 12:615-27.
41. Goodier JL, Ostertag EM, Engleka KA, Seleme MC, Kazazian HH, Jr. A potential role for the nucleolus in L1 retrotransposition. Hum Mol Genet. 2004; 13: 1041-8.
42. Kirilyuk A, Tolstonog GV, Damert A, Held U, Hahn S, Löwer R, Buschmann C, Horn AV, Traub P, Schumann GG. Functional endogenous LINE-1 retrotransposons are expressed and mobilized in rat chloroleukemia cells. Nucleic Acids Res. 2008; 36:648-65.
43. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL. ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 2005; 29:1228-42.
44. Iskow RC, McCabe MT, Mills RE, Torene S, Pittard WS, Neuwald AF, Van Meir EG, Vertino PM, Devine SE. Natural mutagenesis of human genomes by endogenous retrotransposons. Cell. 2010; 141:1253-61.
45. Lee E, Iskow R, Yang L, Gokcumen O, Haseley P, Luquette LJ 3rd, Lohr JG, Harris CC, Ding L, Wilson RK, Wheeler DA, Gibbs RA, Kucherlapati R, et al. Landscape of somatic retrotransposition in human cancers. Science. 2012; 337:967-71.
46. Solyom S, Ewing AD, Rahrmann EP, Doucet T, Nelson HH, Burns MB, Harris RS, Sigmon DF, Casella A, Erlanger B, Wheelan S, Upton KR, Shukla R, et al. Extensive somatic L1 retrotransposition in colorectal tumors. Genome Res. 2012; 22:2328-38.
47. Shukla R, Upton KR, Muñoz-Lopez M, Gerhardt DJ, Fisher ME, Nguyen T, Brennan PM, Baillie JK, Collino A, Ghisletti S, Sinha S, Iannelli F, Radaelli E, et al. Endogenous retrotransposition activates oncogenic pathways in hepatocellular carcinoma. Cell. 2013; 153:101-11.
48. Rodic N, Steranka JP, Makohon-Moore A, Moyer A, Shen P, Sharma R, Kohutek ZA, Huang CR, Ahn D, Mita P, Taylor MS, Barker NJ, Hruban RH, et al. Retrotransposon insertions in the clonal evolution of pancreatic ductal adenocarcinoma. Nat Med. 2015; 21:1060-4.
49. Ergün S, Buschmann C, Heukeshoven J, Dammann K, Schnieders F, Lauke H, Chalajour F, Kilic N, Strätling WH, Schumann GG. Cell type-specific expression of LINE-1 open reading frames 1 and 2 in fetal and adult human tissues. J Biol Chem. 2004; 279:27753-63.
50. Sokolowski M, DeFreece CB, Servant G, Kines KJ, deHaro DL, Belancio VP. Development of a monoclonal antibody specific to the endonuclease domain of the human LINE-1 ORF2 protein. Mob DNA. 2014; 5:29.
51. Suter CM, Martin DI, Ward RL. Hypomethylation of L1 retrotransposons in colorectal cancer and adjacent normal tissue. Int J Colorectal Dis. 2004; 19:95-101.
52. Cho NY, Kim JH, Moon KC, Kang GH. Genomic hypomethylation and CpG island hypermethylation in prostatic intraepithelial neoplasm. Virchows Arch. 2009; 454:17-23.
53. Schulz WA, Elo JP, Florl AR, Pennanen S, Santourlidis S, Engers R, Buchardt M, Seifert HH, Visakorpi T. Genomewide DNA hypomethylation is associated with alterations on chromosome 8 in prostate carcinoma. Genes Chromosomes Cancer. 2002; 35:58-65.
54. Hagan CR, Rudin CM. Mobile genetic element activation and genotoxic cancer therapy potential clinical implications. Am J Pharmacogenomics. 2002; 2:25-35.
55. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature. 2009; 458:719-24.
56. Naas TP, DeBerardinis RJ, Moran JV, Ostertag EM, Kingsmore SF, Seldin MF, Hayashizaki Y, Martin SL, Kazazian HH. An actively retrotransposing, novel subfamily of mouse L1 elements. EMBO J. 1998; 17:590-7.
57. Kearney JF, Radbruch A, Liesegang B, Rajewsky K. A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibodysecreting hybrid cell lines. J Immunol. 1979; 123:1548-50.